Sartorius: Cultural Changes & COVID Disruptions
Former VP of Product Development at Sartorius
inpractise.com/articles/sartorius
Sartorius: Cultural Changes & COVID Disruptions(September 24, 2024)
Former VP of Product Development at Sartorius
Interview Transcript
This is a snippet of the transcript, sign up to read more.
I just wanted to lay that out there with my background and how I'm thinking about the situation. Hopefully, that color helps inform our conversation and gives you a sense of the angle I'm coming from here.
Thank you very much for the introduction. Let me make two or three comments. What really happened with Sartorius is similar to what happened with Rome; they became arrogant. This led to a couple of wrong decisions, really wrong and egoistic decisions, from either René Fáber or Joachim Kreuzburg, which were against all logic, I must say. There was also a lot of restructuring, especially when we joined the DAX. These changes in the structure really destroyed an absolute winning team. We can go into more detail later if you like. The real problem was that we were so busy restructuring that we ended up destroying innovation. Almost no innovation was reaching the market, especially in the FMT - Fluid Management Technology - areas where I was responsible.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher: Cytiva, HyClone, & Cell Culture Sales
Former Sales Specialist at Cytiva
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Danaher: Cytiva & the Chromatography Process
Former Head of Sales, GE Life Sciences
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.